Showing results (3071-3080 of 4,130) with videos related to
Sort By:
Pageof 413
Human Gene Therapy|March 3, 2011
Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinomaRui-Cheng Wei, Xin Cao, Jing-Hua Gui, et al.Human Gene Therapy|June 8, 2010
Generation of human induced pluripotent stem cells bearing an anti-HIV transgene by a lentiviral vector carrying an internal murine leukemia virus promoterMasakazu Kamata, Shirley Liu, Min Liang, et al.Human Gene Therapy|May 26, 2010
Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscleChunping Qiao, Wei Zhang, Zhenhua Yuan, et al.Human Gene Therapy|May 26, 2010
Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scaleMartin Lock, Mauricio Alvira, Luk H Vandenberghe, et al.Human Gene Therapy|May 26, 2010
Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenograftsSuresh Radhakrishnan, Enrique Miranda, Maria Ekblad, et al.Human Gene Therapy|May 22, 2010
Microbead-assisted retroviral transduction for clinical applicationBianca Heemskerk, Annelies Jorritsma, Raquel Gomez-Eerland, et al.Human Gene Therapy|May 22, 2010
Liver-directed recombinant adeno-associated viral gene delivery rescues a lethal mouse model of methylmalonic acidemia and provides long-term phenotypic correctionNuria Carrillo-Carrasco, Randy J Chandler, Suma Chandrasekaran, et al.Human Gene Therapy|May 22, 2010
Transient increase in intrahepatic pressure mediates successful treatment of the Gunn rat with reduced doses of lentiviral vectorFrançoise Schmitt, Maude Flageul, Anne Dariel, et al.Human Gene Therapy|July 24, 2010
Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturingLuk H Vandenberghe, Ru Xiao, Martin Lock, et al.Human Gene Therapy|July 24, 2010
Gene therapy with IgG-HY fusion proteins to reduce male-specific T-cell reactivity in vitroMiranda P Dierselhuis, Ellen Schrama, David W Scott, et al.Pageof 413